®
  • Contact
  • Albumin
  • Products
    • Recombumin®
    • Sample page
  • Albumin Applications
    • COVID-19 Knowledge Hub
    • Cell therapy processing
    • Vaccine stabilization
    • Protein & Peptide formulation
    • Medical device coating
    • Veltis Technology
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

News & Events

World leading manufacturer of recombinant human albumin

Albumedix Media News & Events Reflecting on Fierce JPM and Biotech Showcase 2021

Reflecting on Fierce JPM and Biotech Showcase 2021

01 Feb 2021

Already a month into the year 2021 and we are picking up where we left off, while looking forward to a year where we can get a bit more back to normal.

The first conference attendances this year has continued in the format we have all come to know from 2020 – virtually.

Albumedix US Business Development Directors Brian MacDonald and Gary Willingham attended Biotech Showcase and Fierce JMP respectively, both meetings always at the top of our list every year. It is a place where we usually meet up with both our current partners and collaborators as well as engage with the industry and make new and valuable contacts. Though we are still missing that casual connection over a coffee or in the San Francisco corridors the organizers of both events really managed to keep the high quality of the conference, though in a virtual space.

Both Brian and Gary came back from both virtual attendances with similar first responses – Great partnering systems!

In Albumedix we enable advanced therapies worldwide by being the partner of choice and so we always look at our customers as exactly that, partners. It is therefore extremely important that when we are not able to travel, the systems that support that contact work flawlessly, and so they did. We have all had to adapt to this new way of doing things, but we are all in it together and it was a pleasure connecting with so many people at Fierce JPM and Biotech Showcase again this year.   

As always, the conversations were varied with a broad range of discussions within vaccine development, biopharmaceutical formulation, cell and gene therapies as well as medical devices and diagnostics. Brian and Gary both had a chance to be presented to really cool science at the forefront of innovation. Getting the opportunity to enable and support such technologies is what makes the life of a Business Development Director both fun and inspiring. 

Thank you for a great conference, we look forward to returning again next year!

CONTACT

Albumedix Ltd.
Mabel Street
The Meadows
Nottingham
NG2 3ED, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. We partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with ~100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.

 

Privacy | Cookies | Patent Portfolio

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2018

FOLLOW US

  • Albumin
  • Products
    • Recombumin®
    • Sample page
  • Albumin Applications
    • COVID-19 Knowledge Hub
    • Cell therapy processing
    • Vaccine stabilization
    • Protein & Peptide formulation
    • Medical device coating
    • Veltis Technology
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

We use cookies on our website to improve the website and your experience.

Read more